DSPE-PEG2K-triGalNAc 880157 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000]-N-tri(N-acetylgalactosamine), ammonium salt
Representative Structure
The molecular weight and exact mass are averages based on the polydispersity of PEG.
DSPE-PEG2K-triGalNAc is a PEGylated DSPE lipid functionalized with a tri(N-acetylgalactosamine) (tri-GalNAc) ligand. This molecule enables the precise surface functionalization of liposomes and lipid nanoparticles for ASGPR-mediated hepatocyte (functional liver cell) targeting, a key mechanism in liver-specific delivery.
Avanti Research™ products are manufactured at greater than 99% purity and validated by a certificate of analysis to ensure consistency and confidence in experimental performance. DSPE-PEG2K-triGalNAc is ideal for liver-directed formulations, including siRNA, antisense oligonucleotides (ASO), and gene therapy systems to support the next generation of targeted therapeutic applications.
Key features and technical insights
-
The tri-GalNAc ligand specifically binds the asialoglycoprotein receptor (ASGPR) on hepatocytes.
-
DSPE anchor with PEG2K spacer ensures stable bilayer incorporation and controlled ligand orientation
-
PEG 2000 molecular weight spacer balances circulation time and receptor accessibility
-
High-purity composition (C₁₈₃H₃₅₅N₁₀O₈₁P average) confirmed by analytical validation
-
Optimized for liposome and LNP formulations that require targeted delivery by hepatocytes
Application
DSPE-PEG2K-triGalNAc is for researchers developing liver-specific delivery platforms. As such, it promotes efficient receptor-mediated uptake through ASGPR when integrated into nanoparticle or liposome surfaces. It is an invaluable tool in RNA-based therapies, gene editing technologies, and enzyme replacement systems, thanks to its tri-GalNAc functionalization, which enhances selective internalization by hepatocytes. Recent studies continue to highlight GalNAc-modified lipids as essential tools for precisely targeted drug delivery.
Formulation and handling
Handling procedures are as follows:
- Incorporate into liposome or LNP surfaces at optimized molar ratios (X–Y mol%)
- Store at –20º C; hygroscopic product, may require inert atmosphere handling
- Ammonium salt form for aqueous system compatibility
- Combine with ionizable lipids, cholesterol, and helper phospholipids in hepatocyte-targeted formulations
